<DOC>
	<DOCNO>NCT00147836</DOCNO>
	<brief_summary>The purpose study investigate evaluate effect different intervention ( 1.continuous subcutaneous insulin infusion,2.multiple daily injection , 3.anti-hyperglycemic agent ) glycemic control , B-cell function remission rate newly-diagnosed type 2 diabetic patient .</brief_summary>
	<brief_title>Evaluation Effects Different Interventions Glycemic Control Newly-Diagnosed Type 2 Diabetic Patients</brief_title>
	<detailed_description>ß-Cell dysfunction decrease insulin sensitivity main pathophysiological defect responsible development hyperglycemia . With continuous presence insulin resistance , progressive loss ß-cell function crucial defect . Hyperglycemia deleterious effect β-cell function , partially reversible adequate glycemic control . In newly diagnose type 2 diabetic patient severe hyperglycemia , 2 week continuous subcutaneous insulin infusion ( CSII ) induce adequate glycemic control improvement β-cell function . Nearly half patient maintain euglycemia longer 12 month transient CSII . The improvement β-cell function , especially restoration first-phase insulin response relate sustain euglycemia newly diagnose type 2 diabetic patient . But unclear whether intervention ( oral hypoglycemic agent multiple daily injection ) induce optimal glycemic control short period time effect . As multicenter , open-label , randomize , parallel-group study need prove clarify finding .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>1. informed consent give treatment 2. newlydiagnosed type 2 diabetic patient 3. fast blood glucose ( FBG ) level range 7.0～16.7 mmol/L 4. age range 25～70 year old 5. body mass index ( BMI ) range from20～35kg/m2 6. never treat antihyperglycemic agent antihyperlipidemic agent 1. severe acute chronic complication 2. renal dysfunction , blood creatinine≥150µmol/L 3. blood aminotransferase level rise ( 2 time normal level ) 4. severe cardiac disease include congestive cardiac failure , unstable angina myocardial infarct 12 month 5. serious hypertension ( systolic pressure≥180mmHg and/ diastolic pressure≥110mmHg ) 6. chronic acute pancreatic disease 7. severe systematic disease malignant tumor 8. allergic drug use trial 9. factor interfere result 10. female patient incline pregnant 11. treat corticosteroid , immunosuppressing drug cytotoxic drug 12. poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>therapy</keyword>
	<keyword>sulfonylurea</keyword>
	<keyword>metformin</keyword>
	<keyword>insulin</keyword>
</DOC>